URGENT UPDATE: A Melbourne man, Ralph Markham, is fighting for his life as he turns to new cancer therapies following a devastating multiple myeloma diagnosis. At 65, Ralph is desperate to extend his time with his wife, Cathy Markham, and their blended family.
Just three years ago, Ralph’s life took a dramatic turn. After experiencing unexplained health issues, he received the life-altering news that he had cancer. “I spent the next year getting tests with no clear answers,” Ralph shared. The diagnosis of multiple myeloma, a rare and incurable blood cancer affecting about 22,000 Australians, was a shock to him and his family.
The couple has faced significant challenges since Ralph’s diagnosis, including ineffective treatments and the emotional toll of watching friends succumb to the same disease. “We try to enjoy every moment because you never know how many more moments you have,” Cathy expressed, highlighting the couple’s commitment to making the most of their time together.
In a promising development, Ralph is now looking at new treatment options, including the recently approved Blenrep (belantamab mafodotin), described as a “trojan horse” therapy targeting myeloma cells directly. This groundbreaking drug is the first of its kind approved for multiple myeloma and is expected to significantly improve patient outcomes.
Additionally, the immunotherapy drug Daratumumab (Darzalex) has recently been added to Australia’s Pharmaceutical Benefits Scheme (PBS), dramatically reducing costs from $440,000 to as low as $31.60 per month for eligible patients. This change will enhance access to treatment for nearly 1,200 patients annually.
“Myeloma becomes harder to treat with each relapse, so early therapy is crucial,” said Mark Henderson, CEO of Myeloma Australia. “Blenrep provides a new choice, and we welcome its availability for eligible patients.” This news is a beacon of hope in a landscape where the five-year survival rate for myeloma patients remains below 61%.
Ralph has been proactive in his battle against cancer, actively participating in clinical trials and support groups. “I’m always keeping up with new treatments and clinical studies,” he remarked, expressing optimism for a future where a cure could be within reach.
As the Markhams continue to navigate their challenges, they also remain committed to their community, raising funds through half-marathons and volunteering for Myeloma Australia. “Every new treatment is another chance,” Ralph emphasized, underscoring the importance of continued advocacy and support for those affected by myeloma.
With new therapies on the horizon and a growing community of support, Ralph and Cathy Markham’s journey highlights the urgent need for advancements in cancer treatment and the profound impact these developments can have on patients’ lives. As the fight against multiple myeloma continues, every breakthrough brings renewed hope.
